Cervical and ovarian cancer patients with lower PRMT1 levels were likely to benefit more from cisplatin-based chemotherapy and had a longer overall survival period when compared to the patients with high PRMT1 expression (Matsubara et al., 2021; Shimomura et al., 2021). This evidence concerns the gene PRMT1 and ovarian carcinoma.